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Abstract The expression of apoptosis genes in a com-
mercial pre-designed low-density array from Applied
Biosystems was evaluated in two human brain cancer cell
models, LN-18 and Daoy (HTB-186TM) in comparison to
the reference human primary endothelial cells under basic
conditions. Analysis of the gene expression in the cancer
cell lines compared to the normal control revealed features
reflecting anti-apoptotic and inflammatory characteristics
of the former. There was an overall downregulation of
apoptosis-stimulating genes in both cancer cell lines, along
with an upregulation of certain apoptosis inhibitors. A
number of genes demonstrated statistically significant
changes in their expressions, including BAX (BCL2-asso-
ciated X protein); the CARD4/NLR family, CARD domain
containing 4; CASP10 (caspase 10, apoptosis-related cys-
teine peptidase); DAP1 (death-associated protein kinase 1),
and BIRC5 (baculoviral IAP repeat-containing 5). Anti-
apoptotic potential in both cell lines was demonstrated by
changes in the Bax:Bcl-2 ratio and downregulation of the
APAF1 gene in LN18 cells. There was also significant
downregulation of extrinsic signals and the TNF/FADD/
inflammatory cascade, and upregulation of caspase inhib-
itors (IAPs). These results provided a novel molecular
characterization of important human cancer cell lines,
which might provide a useful research tool for investigat-
ing the experimental model of the CNS cell.
Keywords Apoptosis  Models for brain cell
research  LN18  Daoy  Inflammation  Brain cancer
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Introduction
Human cancer research heavily relies on molecular biol-
ogy, which, among other methods, includes controlled
studies in culture cell lines. Even though typical commer-
cially available cell lines often differ from normal and
cancer cells, difficult access to human tumor and/or human
normal tissue makes them useful and popular experimental
models. Two standard tumor brain cell lines from the
American Type Culture Collection, LN18, derived from
glial cells (supportive tissue of the brain) and Daoy,
derived from the neural stem cell precursors, are widely
used in studies that employ experimental models of brain
neoplastic disease.
Medulloblastoma, the most common malignant brain
tumor in children, is a primitive neuroectodermal tumor
arising in the cerebellum. The aggressive clinical behavior
of the tumor along with the cognitive and endocrinological
long-term side effects of current therapies mean that both
the development of prognostic indicators for disease
stratification and the identification of new therapeutic tar-
gets represent major goals. Current understanding of the
molecular biology of medulloblastoma is limited. Cytoge-
netic studies have described consistent chromosomal
aberrations, but molecular genetic studies have identified
specific genetic and epigenetic abnormalities in only a
small proportion of those tumors (reviewed in [1–3]). The
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Daoy cell line was established in 1985 by P.F. Jacobsen of
the Royal Perth Hospital in Western Australia. The line
was derived from the biopsy material taken from a tumor in
the posterior fossa of a four-year-old boy. Although the
original tumor presented characteristics of both neuronal
and glial phenotypes, these were not retained by the Daoy
cell line [4].
Gliomas are the most frequent and lethal cancers orig-
inating in the central nervous system in adults. The LN-18
cell line was established in 1976 from the cells of right
temporal lobe glioma. The cells are poorly differentiated
[4–7] and negative for glial fibrillary acidic proteins and
S100 (S-100) protein [5]. They exhibit mutated p53 (TP53)
and possible homozygous deletions in the p16 and p14ARF
tumor suppressor genes, and have a wild-type PTEN gene
[6]. Stimulation of the cells with Fas ligand leads to
apoptotic cell death within 16 h. Overexpression of Bcl-2
protects these cells from Fas ligand-induced cell death.
This cell line is frequently used in apoptosis studies [8].
Apoptosis can result from the activation of multiple
pathways that differ according to tissue type and patho-
logical condition. They have been identified and classified
into two main types: extrinsic and intrinsic pathways. Both
pathways converge finally at the level of the activation of
caspases, the effector molecules in most forms of cell death.
The extrinsic pathways include death-receptor and survival-
factor withdrawal pathways. The first is activated by the
stimulation of certain membrane receptors such as TNF-
alpha and Fas receptors, while the latter involves the acti-
vation of c-Jun and JNK. Research efforts for the past two
decades have revealed the existence of a superfamily of 18
genes encoding 19 TNF ligands that signal through 30
receptors. One ligand has been found to bind to as many as
five different receptors. This superfamily is associated with
several disease conditions, including acute and chronic
inflammatory and genetic diseases [10–12]. The TNF
family and its corresponding receptors play important roles
in cell death or survival, proliferation, and maturation. A
specific characteristic of all members of the TNF super-
family is that, through the recruitment of TNF receptor-
associated factors (TRAFs), they all activate NFkB, a
transcription factor that causes the suppression of apoptosis,
cell survival, and proliferation. Some TNF ligands can
activate both apoptosis and anti-apoptosis cell survival
pathways under certain conditions. The balance between
these two types of pathways gives this superfamily the
ability to act as a switch for cell death or survival [11, 13].
The Bcl2 family consists of approximately 15 proteins.
The family can be divided into anti-apoptotic and pro-
apoptotic subgroups that share one or more Bcl2 homology
domains (BH1–BH4). The anti-apoptotic members, which
include Bcl2, Bcl-xL (the long isoform encoded by
Bcl2l1), Bcl-W (Bcl2l2), Mcl1, and A1/Bfl1 (Bcl2a1), all
share BH1 and BH2 domains. They are thought to exert
their effects by stabilizing the mitochondrial membrane
potential and preventing the release of cytochrome c and
apoptosis inducing factor (AIF). Bcl2 and Bcl-xL can block
cell death caused by a wide variety of apoptotic stimuli,
such as chemotherapeutic drugs, ultraviolet radiation, heat
shock, free radicals, calcium ions, TNF, and interleukin-3
[14–16]. The pro-apoptotic members, which include Bax,
Bak, Bok, Bid, Bad, Bcl-xS (the short isoform encoded by
Bcl2l1), Bim (Bcl2l11), Bik, Blk, and Hrk, have the BH3
domain, which is necessary for their pro-apoptotic effect.
Interactions between anti-apoptotic and pro-apoptotic
members of the Bcl2 family determine the sensitivity of a
cell to apoptosis [17–20]. While Bcl-xL (Bcl2l1) appears to
be the most dominant anti-apoptotic factor in the devel-
oping central nervous system and adult neurons, both Bcl2
and Bcl-xL are expressed in embryonic neurons [21]. Bcl-
xL expression levels have been found to be high prior to
birth, undetectable in the neonatal tissue, low in young
adult brain, and elevated again in the aged human brain
[22], while the overexpression of Bcl2 prevents cell death.
The release of cytochrome c into the cytoplasm results
in the activation of an apoptosome complex composed of
APAF1, cytochrome c, and deoxy-ATP. This complex
stimulates caspases and initiates cell death by breaking up
different cell proteins and DNA fragments through CAD
(caspase activated DNase)-mediated degradation.
Caspases are a family of cysteine proteases that play a
critical role in human cell apoptosis, the activation of
cytokines, and the induction of inflammation. To date, 11
human caspases have been identified. They are divided into
two main classes: upstream or initiator caspases (Casp1, 2,
4, 5, 8, 9, 10, 12, 13), and downstream or effector caspases
(Casp3, 6, 7). Upstream caspases are responsible for cas-
pase activation or regulation of inflammatory processes.
They share long N-terminal pro-domains, caspase recruit-
ment domains (CARDs), or death effector domains
(DEDs). Downstream caspases cause the actual destruction
of the cell, and they tend to have short or absent domains
[23]. Another classification categorizes caspases into
interleukin-1b converting enzyme (ICE) caspases (human
Casp1, 4, 5, 13, 14 and mouse casp11 and 12) and CED-3
caspases (Casp 3, 6, 7, 8, 9 and 10) [24, 25]. Overexpres-
sion of either caspase 1 or 11 induces apoptosis, which can
be prevented by Bcl2. Unlike caspase 1, caspase 11
mediates the lipopolysaccharide (LPS) neurotoxicity [26]
and regulates cell migration [27]. In Fas- and TNF-medi-
ated apoptosis, the Casp1 protease family seems to act
downstream of caspase 8 and caspase 10, and upstream to
the caspase 3 protease family [28]. Human caspase 4 may
also be involved in a different apoptotic pathway, since it
has been activated by agents that cause stress of the
endoplasmic reticulum (ER), inducing the activation of
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caspase 3 [25]. The proteolytic activity of caspases is
tightly controlled by the inhibitors of apoptosis protein
family (BIRC/IAP), which have evolved to protect cells
from unwanted self-execution through chance activation of
the death cascade.
Our study is based on the fact that patterns of expression
of known genes can reveal novel phenotypic aspects of the
cells and tissues studied. The predefined apoptosis gene
signature was studied in Daoy medulloblastoma cells,
LN18 glioblastoma cells, and primary human umbilical
vein endothelial cells (HUVEC) using commercial
384-well format microfluidic cards (TLDA TaqMan
human apoptosis array from Applied Biosystems) based on
the RT-PCR reaction.
Methods
Cell culture
The human glioblastoma cell line originating from right
temporal lobe cells (LN18) (ATCC, CRL-2610) cultured in
Dulbecco’s modified Eagle’s medium (ATCC) with 5%
foetal bovine serum, FBS (Clonetics), and human medul-
loblastoma cells (Daoy) (ATCC, HTB-186) cultured in
Eagle’s minimum essential medium (ATCC, 30-2003) with
10% FBS (Clonetics) were used. Cells were cultured at
37C with 95% humidity and 5% CO2.
Additionally, as a reference, primary human umbilical
vein endothelial cells (HUVEC) were isolated from the
umbilical cords using collagenase digestion according to
Jaffe et al. [9]. The HUVECs were cultured in EBM (EGM
Bullet Kit, Clonetics) with supplements: hEGF (10 ng/ml),
hydrocortisone (1 ng/ml), bovine brain extract (12 lg/ml),
antibiotics: gentamicin (50 lg/ml) and amphotericin B
(50 ng/ml), and 10% FBS (Clonetics). HUVECs up to the
fifth passage were used for the experiments. Cells were
cultured at 37C with 95% humidity and 5% CO2.
The microarray study (TaqMan human apoptosis
array: Applied Biosystems TLDA)
The regulation of gene expression was studied in triplicate
(three different experiments on three separate TLDA
plates), using predesigned 384-well microfluidic cards
(TLDA TaqMan human apoptosis array from Applied
Biosystems) based on the RT-PCR reaction.
RNA extraction and reverse transcription
Total RNA from the experimental and control cells was
isolated by a TRIzol Plus RNA purification system (cat.
no. 12183-555, Invitrogen). The RNA isolation quality was
checked by NanoDrop. Five micrograms of total RNA
were reverse transcribed in a total volume of 15 ll using
the First-Strand DNA synthesis kit according to the man-
ufacturer’s guidelines (cat. no. 4368814, Applied
Biosystems).
The qRT-PCR based TaqMan low-density array
(TLDA)
The predesigned 384-well microfluidic cards with eight
sample loading ports were used (TLDA TaqMan human
apoptosis array, Applied Biosystems, cat. no. 4378701).
The TLDA cards were configured into four identical
96-gene sets measured in triplicate. The TaqMan low-
density array human apoptosis panel contained assays for
93 human genes in addition to three endogenous controls
(18S, ACTB, GAPDH). The primer sets (TaqMan Gene
Expression Assay, Applied Biosystems) were selected so
that they generated amplicons that were no longer than
100 bp (mean 74 bp). The 93 genes were categorized into
multiple target classes or pathways including intrinsic,
extrinsic, regulatory, and execution apoptosis traits. A
reaction mixture with cDNA template (100 ng) and an
equal volume of TaqMan universal master mix (Applied
Biosystems) was immediately loaded into each line of the
TLDA microfluidic card. Each card was spun twice at
1,200 rpm for 1 min each time to distribute the PCR mix
into the wells of the card, before it was sealed and loaded
into the ABI 7900HT fast real-time PCR system. The
thermal cycle conditions were as follows: 2 min at 50C,
10 min at 94.5C, 30 s at 97C, and 1 min at 59.7C for 40
cycles.
Array normalization and selection of differentially
expressed genes from microarray data
The arithmetic standard normalization procedures rec-
ommended by the Data Assist software for microarray
data were followed. In brief, data transformation was
corrected for the signal from the three endogenous con-
trols (18S, ACTB, GAPDH). Per card (mean) normali-
zation accounted for the variability of each card by
dividing all of the measurements on each card by the
value of the 50th percentile. Per gene normalization
accounted for the variability between probe sets for the
three reporter genes.
The threshold cycle, Ct, was automatically assigned by
the SDS2.2 software package (Applied Biosystems). Rel-
ative quantities (RQ) were determined using the equation
RQ = 2 - DDCt. All data were generated in triplicate
(different TLDA plates) and expressed as the mean ± SD.
Differentially expressed genes were selected from the
normalized data using a procedure known as significance
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analysis of microarrays, as installed in the SDS2.3 software
package (Applied Biosystems). Genes were considered to
be significant when their average fold change (FC) was
B-1.5 or C1.5, and statistically significant when the cor-
responding p value was B0.05. Two software programs
were used to analyze the data, namely SDS RQ Manager
1.2 and DataAssist v.2.2 software (Applied Biosystems).
MetaCoreTM software (from GeneGo) was used to per-
form pathway analysis of the differentially expressed
genes.
Results
The expressions of the 93 genes that constitute the most
significant apoptosis and apoptosis signal pathway-related
genes were studied in the LN18 and Daoy cell lines using
TaqMan low-density arrays prepared as predesigned
384-well microfluidic cards with eight sample loading
ports (TLDA TaqMan human apoptosis array, Applied
Biosystems, cat. no. 4378701). Three internal controls,
which included glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), 18S rRNA and beta-actin (ACTB)
were used for data normalization. Every cell line was
evaluated in triplicate, in three independent cell cultures.
The results were expressed as the mean values of the three
experiments.
Evaluation of differential gene expression
by low-density arrays
Table 1 and Fig. 1 show the mean fold change (FC) in
expression of the particular gene relative to the mean of the
control non-cancer group (HUVECs) as a reference.
ANOVA analysis with Bonferroni correction was used to
determine statistical significance (p).
The anti-apoptotic characteristics of LN18 cells are
supported by the downregulation of several genes from the
membrane stress receptors, such as TNFRSF1B,
TNFRSF10B, TNFRSF10A, along with CFLAR, which is
a downstream regulator of caspase 8 activity. In Daoy cells,
the regulation of the TNF receptor pathway was not sig-
nificantly affected, but there was a modest upregulation of
NFkB family members (RELB, NFKBIA, NFKBIB).
Enhancement of the NFkB signaling pathway suggested a
decline in inflammatory processes and strong anti-apopto-
tic properties for this cell line.
The regulation of both pathways—apoptotic and
inflammatory—may subsequently result in the inactivation
of certain signal cascades, and ultimately lead to cell sur-
vival through their stabilizing effect on the mitochondrial
membrane (decrease in Bax, and increase in the Bcl and
Bcl-xL families) and downregulation of caspase 10.
Pathway analysis
Pathway analysis was performed only for genes for which
the fold change in their normalized expressions (compared
to control HUVECs) reached the significance threshold of
\-1.5 or [1.5. MetaCoreTM software (from GeneGo;
http://www.genego.com/metacore.php) was used for this
analysis. ANOVA with Boferroni correction identified
statistically significant changes in gene expression, which
were visualized on the pathway maps.
Tumor necrosis factor (TNF) and TNF receptor family
pathway
The expression patterns of the genes that were significantly
different in LN18 and Daoy cells compared to reference
HUVEC cells reflect the anti-apoptotic properties of the
cancer cells as mediated by the TNF receptor family
pathway (Fig. 2). In LN18 cells, there was the most pro-
nounced decrease in TNFR2 expression, followed by
downregulation of TNFRSR10A (DR4), TNFRSR10B
(DR5), TNFRSR21 (DR6), and FADD. There were some
less evident changes in TNFR-related gene expression in
Daoy cells, in which TNFRSF10B (DR5) and FADD were
downregulated while TNFR1 was upregulated.
Only the downregulation of TNFRSF1B (FC = -19.42,
p = 0.01) and that of TNFRSF10B (FC = -2.73,
p = 0.01) in LN18 cells were statistically significant
(Table 1).
NFkB signaling pathway
Both cancer cell lines demonstrate altered regulation of the
NFkB signaling pathway, since there is generally increased
expression of the main component of NFkB complexes:
RELA (p65), its inhibitors: KBKE, kinase of inhibitors
CHUK, and kappa light polypeptide gene enhancer in
B-cells 3, p65: NFKBIA and NFKBIB. In addition, there
was increased expression of IKBKG and NFKB1, and a
decrease in TBK-1 in the LN18 cell line. In Daoy cells,
NFKB2 (p52), REL, RELA (p65), RELB, IKBKE, CHUK,
and TBK1, a serine/threonine phosphatase that leads to the
activation of NFkB, were all upregulated in comparison to
control HUVECs. Protein Bcl-3, the expression of which is
upregulated in both cancer cell lines, may bind to NFKB1
and NFKB2 homodimers and form complexes that function
as transcriptional activators.
The changes in NFkB pathway gene expression were
statistically significant in the group of inducers of inflam-
matory response. NFKBIA was decreased in LN18
(FC = -1.86, p = 0.048) and increased in Daoy cells
(FC = 2.11, p = 0.0013), IKBKG was increased
(FC = 2.3, p = 0.0012) in LN18 cells, while RELB
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Table 1 Differentially expressed genes in the LN18 and Daoy cell lines. HUVEC cells were used as reference
Gene name Ensembl gene
number
LN18 (fold
change)
p Daoy
(fold
change)
p Gene description
TNF receptor pathway
TNFRSF1A ENSG00000067182 5.85 0.4526 Tumor necrosis factor receptor superfamily, member 1A
TNFRSF1B ENSG00000028137 -19.42 0.0159 -1.56 0.4410 Tumor necrosis factor receptor superfamily, member 1B
TNFRSF10B ENSG00000120889 -2.73 0.0179 Tumor necrosis factor receptor superfamily, member 10b
TNFRSF10A ENSG00000104689 -3.62 0.2720 Tumor necrosis factor receptor superfamily, member 10a
TNFRSF21 ENSG00000146072 -1.68 0.1542 Tumor necrosis factor receptor superfamily, member 21
RIPK2 ENSG00000104312 -2.37 0.4262 Receptor-interacting serine-threonine kinase 2
FAS ENSG00000026103 2.57 0.2923 2.70 0.0736 Fas (TNF receptor superfamily, member 6)
LRDD ENSG00000177595 1.53 0.4948 Leucine-rich repeats and death domain containing
FADD ENSG00000168040 -3.13 0.4149 -2.46 0.4763 Fas (TNFRSF6)-associated via death domain
NF-jB signaling pathway
IKBKG ENSG00000073009 2.30 0.0012 Inhibitor of kappa light polypeptide gene enhancer in
B-cells, kinase gamma
IKBKE ENSG00000143466 3.30 0.4973 4.53 0.0665 Inhibitor of kappa light polypeptide gene enhancer in
B-cells, kinase epsilon
NFKB1 ENSG00000109320 1.95 0.5487 Nuclear factor of kappa light polypeptide gene enhancer
in B-cells 1
NFKB2 ENSG00000077150 2.95 0.1673 Nuclear factor of kappa light polypeptide gene enhancer
in B-cells 2 (p49/p100)
TBK1 ENSG00000183735 -1.80 0.0835 1.90 0.0670 TANK-binding kinase 1
CHUK ENSG00000213341 1.64 0.0817 11.71 0.3812 Conserved helix–loop–helix ubiquitous kinase
REL ENSG00000162924 13.19 0.4201 v-rel reticuloendotheliosis viral oncogene homolog
(avian)
RELA ENSG00000173039 1.71 0.3595 1.73 0.4992 v-rel reticuloendotheliosis viral oncogene homolog A
(avian)
RELB ENSG00000104856 4.51 0.0148 v-rel reticuloendotheliosis viral oncogene homolog B
Kappa light polypeptide gene enhancer in B-cells 3, p65
NFKBIA ENSG00000100906 -1.86 0.0483 2.11 0.0013 Nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, alpha
NFKBIB ENSG00000104825 1.58 0.3221 2.33 0.0192 Nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, beta
NFKBIZ ENSG00000144802 6.33 0.1677 Nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, zeta
LTB ENSG00000206437 -2.23 0.0000 Lymphotoxin beta (TNF superfamily, member 3)
Bcl-2 family-regulated pathway
BCL10 ENSG00000142867 -2.94 0.0956 1.55 0.4350 B-cell CLL/lymphoma 10; hypothetical LOC646626
BCL2 ENSG00000171791 4.15 0.2941 B-cell CLL/lymphoma 2
BCL2L11 ENSG00000153094 1.51 0.2924 2.14 0.0856 BCL2-like 11 (apoptosis facilitator)
BCL2L2 ENSG00000129473 1.76 0.0521 BCL2-like 2
BCL2L1 ENSG00000171552 -1.58 0.3776 BCL2-like 1
BIK ENSG00000100290 7.02 0.0006 BCL2-interacting killer (apoptosis-inducing)
PMAIP
(NOXA)
ENSG00000141682 6.38 0.0906 2.44 0.1623 Phorbol-12-myristate-13-acetate-induced protein 1
BAX ENSG00000087088 -3.06 0.0001 -2.78 0.0003 BCL2-associated X protein
BAK1 ENSG00000030110 1.89 0.0658 3.48 0.3774 BCL2-antagonist/killer 1; BCL2-like 7 pseudogene 1
BCL3 ENSG00000069399 2.04 0.3101 1.74 0.0769 B-cell CLL/lymphoma 3
BBC3
(PUMA)
ENSG00000105327 -3.66 0.0124 -1.51 0.4215 BCL2 binding component 3
BID ENSG00000015475 2.50 0.0140 3.12 0.0197 BH3 interacting domain death agonist
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(FC = 4.51, p = 0.014) and NFKBIB (FC = 2.33,
p = 0.01) were upregulated in Daoy cells.
BCL2 family, mitochondrial pathway
The significantly lower expression of the BAX gene,
shown in Fig. 3, may indicate increased anti-apoptotic
properties of both Daoy and LN18 cells. Our findings
demonstrated increased expression of Bcl-xL and Bcl2 in
Daoy cells, in which they serve as protective factors
against apoptosis. In both cell lines, the BBC3 (PUMA)
and BAX genes were downregulated. There was also a
significant decrease in BOK gene expression and moderate
downregulation of BNIP3L and BCL2L1 in the Daoy cell
line. Genetic analysis also revealed significant upregulation
of the PMAIP (NOXA), BNIP3, BID, BAK1, BCL2L11
Table 1 continued
Gene name Ensembl gene
number
LN18 (fold
change)
p Daoy
(fold
change)
p Gene description
BNIP3 ENSG00000176171 5.82 0.0787 BCL2/adenovirus E1B 19 kDa interacting protein 3
BNIP3L ENSG00000104765 -2.57 0.0034 BCL2/adenovirus E1B 19 kDa interacting protein 3-like
MCL1 ENSG00000143384 1.57 0.0822 Myeloid cell leukemia sequence 1 (BCL2-related)
BOK ENSG00000176720 -8.21 0.0216 BCL2-related ovarian killer
CARD family
CARD4 ENSG00000106100 -3.65 0.2323 -1.60 0.5178 NLR family, CARD domain containing 1
CARD6 ENSG00000132357 -8.99 0.0703 -8.26 0.0726 Caspase recruitment domain family, member 6
PYCARD ENSG00000103490 -1.71 0.1412 PYD and CARD domain containing
NALP1 ENSG00000091592 2.69 0.3319 Pyrin domain containing 1
APAF1 ENSG00000120868 -1.60 0.0869 1.61 0.4612 Apoptotic peptidase activating factor 1
Caspases
CASP1 ENSG00000137752 3.51 0.0071 3.47 0.3375 Caspase 1, apoptosis-related cysteine peptidase
(interleukin 1, beta, convertase)
CASP2 ENSG00000106144 1.55 0.1557 Caspase 2, apoptosis-related cysteine peptidase
CASP3 ENSG00000164305 -1.84 0.0099 Caspase 3, apoptosis-related cysteine peptidase
CASP4 ENSG00000196954 1.84 0.0401 Caspase 4, apoptosis-related cysteine peptidase
CASP6 ENSG00000138794 -4.90 0.0558 Caspase 6, apoptosis-related cysteine peptidase
CASP7 ENSG00000165806 -2.63 0.0039 Caspase 7, apoptosis-related cysteine peptidase
CASP8 ENSG00000064012 5.32 0.0333 2.22 0.0746 Caspase 8, apoptosis-related cysteine peptidase
CASP8AP2 ENSG00000118412 1.91 0.1153 Caspase 8 associated protein 2
CASP9 ENSG00000132906 3.29 0.2507 Caspase 9, apoptosis-related cysteine peptidase
CASP10 ENSG00000003400 -4.50 0.0030 -15.80 0.0018 Caspase 10, apoptosis-related cysteine peptidase
CFLAR ENSG00000003402 -19.61 0.0354 -5.82 0.0522 CASP8 and FADD-like apoptosis regulator
IAP family
BIRC2 ENSG00000110330 4.00 0.4295 Baculoviral IAP repeat-containing 2
BIRC3 ENSG00000110330 -2.15 0.5738 2.60 0.1416 Baculoviral IAP repeat-containing 3
BIRC4 ENSG00000110330 -3.11 0.4686 Baculoviral IAP repeat-containing 4
BIRC5 ENSG0000008968 3.50 0.0000 2.70 0.0000 Baculoviral IAP repeat-containing 5
BIRC6 ENSG00000115760 2.09 0.0265 Baculoviral IAP repeat-containing 6
BIRC8 ENSG00000180152 4.13 Baculoviral IAP repeat-containing 8
Others
HIP1 ENSG00000127946 -1.84 0.0150 Huntingtin interacting protein 1
DAPK1 ENSG00000196730 -27.70 0.0061 -2.08 0.0531 Death-associated protein kinase 1
DEDD ENSG00000158796 -1.54 0.1765 1.87 0.1560 Death effector domain containing
DIABLO ENSG00000184047 1.74 0.0082 1.94 0.0181 Homo sapiens diablo homolog (Drosophila)
ESRRBL1 ENSG00000114446 2.11 0.2580 HIP1 protein interactor
HTRA2 ENSG00000115317 1.54 0.2200 HtrA serine peptidase 2
ANOVA analysis with Bonferroni correction was used to determined statistical significance
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genes in LN18 and BNIP3, BIK, BCL2, BAK1, BID,
PMAIP (NOXA), BCL2L11, and BCL2L2 in Daoy cells.
The most statistically significant changes in the mito-
chondrial pathway were discovered in BAX (BCL2-asso-
ciated X protein) gene expression, which was decreased in
both LN18 cells (FC = -3.66, p = 0.0001) and Daoy cells
(FC = -2.78, p = 0.0003), and BID, which showed ele-
vated gene expression (LN18, FC = 2.5, p = 0.014; Daoy,
FC = 3.12, p = 0.019). The other factors included PUMA,
which was downregulated in LN18 cells, and a group of
genes that showed either elevated (BIK) or decreased
(BNIP3L, BOK) expression in Daoy cells.
Caspase family: executive pathway
Our results show that caspase 4 (also known as caspase
11 or inflammatory caspase) is upregulated in Daoy cells,
but it does not seem to play any important causative role
in the activation of caspase 3, since the latter is down-
regulated. Some of the anti-apoptotic effects may be
reflected in the downregulation of caspases 7 and 10 in
Daoy cells and caspases 6 and 10 in LN18. The expres-
sion of the CFLAR gene, which is an apoptosis regulator
that may function as a crucial link between cell survival
and cell death pathways in mammalian cells, is down-
regulated in both cancer cell lines (in comparison to
HUVECs) (Fig 4; Table 1).
The statistically significant changes in the caspase
executive pathway were noted. Most of the caspase gene
expression changes were statistically significant in LN18
cells. The CASP3, CASP10, and CFLAR genes were
downregulated, while CASP1, CASP4, and CASP8 were
slightly increased. The only significant alterations in gene
expression were seen in the negative fold changes of the
CASP7, CASP10, and CFLAR genes in Daoy cells.
Inhibitors of apoptosis BIRC proteins
BIRC proteins (baculovirus IAP repeat containing proteins)
are members of the inhibitor of apoptosis (IAP) gene
family which encode negative regulatory proteins that
prevent apoptotic cell death. The proteolytic activity of
caspases is tightly controlled by the family of inhibitors of
apoptosis (BIRC/IAP), which were typically upregulated in
the studied cancer cell lines (Table 1). The gene expression
of BIRC2 and BIRC5 was increased in LN18, whereas
BIRC3, BIRC5, BIRC6, and BIRC8 were elevated in Daoy
cells.
The distinct increase in the fold change in BIRC5
expression was statistically significant in both cancer cell
lines compared to the control HUVEC cells. There was also
clear upregulation of the BIRC6 gene (FC = 2.09,
p = 0.026) in Daoy cells.
CARD family: the caspase recruitment domains
Caspase recruitment domains, or caspase activation and
recruitment domains (CARDs), are interaction motifs
Fig. 1 List of the genes for which expression in LN18 and Daoy cells
was significantly different from the control HUVEC cells. The genes
are divided into indicated apoptosis pathways: the TNF receptor
pathway, NKkB signaling pathway, Bcl-2 family-regulated pathway,
CARD family, caspases, IAP family, and others. Differences in gene
expression are presented as fold changes (compared to reference
HUVECs), accompanied by corresponding p values (according to
[36])
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found in a wide array of proteins, typically those
involved in processes relating to inflammation and
apoptosis. These domains mediate the formation of larger
protein complexes via direct interactions between indi-
vidual CARDs.
There were several members of the CARD family of
genes that were substantially downregulated in the two
analyzed cancer lines. Negatively affected genes included
CARD4, CARD6, APAF1, and BCL10 in neuronal LN18
cells, and CARD4, CARD6, and PYCARD in the Daoy cell
line (Table 1). There was also noticeable but marginal
upregulation of NALP1, APAF1, and BCL10 in Daoy cells.
None of the observed fold changes in gene expression were
statistically significant.
DED domain genes
DAPK1 (death-associated protein kinase 1) is a multi-
domain Ser/Thr protein kinase that plays an important role
in apoptosis regulation, and the DEDD death effector
domain is a protein–protein interaction domain shared by
adaptors, regulators, and executors of the programmed cell
death pathway.
DAPK1 was statistically significantly downregulated in
both studied cancer cells, in particular LN18 (FC = -27.7,
p = 0.006). Gene expression of DEDD was modestly
decreased in LN18 cells, in contrast to its increase in Daoy
cells. There was also slight but statistically significant fold
change increases in the expression of DIABLO (Homo
Fig. 2 The MetacoreTM apoptosis signaling pathway relating to TNF
receptors, NFkB and BCL-2 antiapoptotic family genes. Bars indicate
the degree of up- or downregulation of the gene target relative to
HUVEC cells; means decreased gene expression. means increased
gene expression; height of bars corresponds to the change value.
Numbers in symbols indicate: 1 LN18, 2 Daoy cell lines; number of
asterisks reflects the statistical significance of the p value (* p \ 0.05,
** p \ 0.01, *** p \ 0.001)
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sapiens diablo homolog) in both LN18 (FC = 1.74,
p = 0.008) and Daoy (FC = 1.94, p = 0.018) cells.
Discussion
The two brain cancer cell lines Daoy and LN18 are widely
used in many studies of cancerogenesis and apoptosis. The
goal of our study was to analyze pro- and anti-apoptotic
gene expression using the commercially available set of
genes included in the low-density microarray card supplied
by Applied Biosystems. The results presented above show
the differences between human brain cancer cells and non-
cancer cells of endothelial origin.
Current understanding of the molecular phenotypes of
medulloblastoma and glioblastoma is still limited, so our
gene expression signatures may increase knowledge about
the mechanisms of malignant transformation, physiology,
and increase the number of potential therapeutic
approaches.
Perturbation of apoptosis can lead to excessive cell
survival, and can contribute to carcinogenesis [29, 30]. Our
study demonstrates the anti-apoptotic properties of both
cancer cell lines at the gene expression levels. Such an
Fig. 3 The MetacoreTM apoptosis signaling pathway relating to
mitochondrial proteins. Bars indicate the degree of up- or downreg-
ulation of the gene target relative to HUVEC cells; means decreased
gene expression. means increased gene expression; height of bars
corresponds to the change value. Numbers in symbols indicate: 1
LN18, 2 Daoy cell lines; number of asterisks reflects the statistical
significance of the p value (* p \ 0.05, ** p \ 0.01, *** p \ 0.001)
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expression signature is a good mirror of the genetic and
epigenetic abnormalities characteristic of the molecular
phenotypes of different cell lines.
DAPK1 gene expression was significantly lower in the
two studied cancer cell lines in comparison with the non-
cancer endothelial cells. The low expression of DAPK1
was regarded as principlally an anti-apoptotic phenome-
non, which has been previously observed in many cancer
cells [31, 32]. It was hypothesized that Ded protein, a
product of DAPK1 gene, might cause cell immortalization
and determine malignancy in cancers [32].
LN18 and Daoy cells display anti-apoptotic properties,
as exemplified by the regulation of the expression of sev-
eral apoptotic genes. Different types of human tumors
manifest a deregulated NFjB signaling pathway, where
NFjB is constitutively active. There was overexpression of
many genes which encode proteins that are either members
of the NFkB signaling pathway or its regulators. Active
NFjB stimulates the expression of the genes that maintain
cellular proliferation and protect cells from the conditions
that would otherwise cause their apoptosis [1–3].
Our results demonstrate a number of statistically sig-
nificant changes in the genes related to any of the aspects of
the apoptotic pathway. In addition to the genes listed
above, the most pronounced fold changes in gene expres-
sion were noted in CASP10, CFLAR, BAX, and BID.
LN18 cells differed from the Daoy cell line in their more
pronounced regulation of the genes encoding the TNF
receptor pathway and caspase family. Such a gene
expression pattern might provide the neuronal LN18 cells
Fig. 4 The MetacoreTM apoptosis signaling pathway relating to
caspase activation. Bars indicate the degree of up- or downregulation
of the gene target relative to HUVEC cells; means decreased gene
expression. means increased gene expression; height of bars
corresponds to the change value. Numbers in symbols indicate: 1
LN18, 2 Daoy cell lines; number of asterisks reflects the statistical
significance of the p value (* p \ 0.05, ** p \ 0.01, *** p \ 0.001)
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with an advantageous control over inflammatory processes
as well.
The dynamic balance between relative amounts of pro-
and anti-apoptotic proteins is believed to be the key
determinant in the regulation of cell death and survival
[33–35]. Thus, the presented differences in basal condition
gene expression should be considered when either LN18 or
Daoy cell lines are selected as models in molecular struc-
tural and/or functional studies of other factors.
We showed in our work that endothelial cells are more
susceptible to apoptosis than glioblastoma and medullo-
blastoma. Endothelial cells (ECs) are also ubiquitous
within tumors because tumors are vascular, and yet, the
impact of tumor-resident ECs is less well understood.
Radical therapy, which is usually used in the treatment of
many kinds of tumors due to its pro-apoptotic properties,
may influence not only tumor cells but also first line
endothelial cells, inhibiting its influence on cancer growth.
Cancer growth and metastasis are regulated in part by
stromal cells such as fibroblasts and immune cells within
the tumor microenvironment. In our work, HUVEC cells
were used as a model of endothelial cells. Endothelial cells
play a crucial role in tumor angiogenesis, which is neces-
sary for solid tumor progression and metastasis. Through
paracrine regulation, ECs modulate a diverse spectrum of
pathophysiologic processes in normal and hyperplastic
tissues. ECs offer similar paracrine regulatory control of
cancer biology. Indeed, secretions from quiescent ECs
muted the proliferative and invasive phenotype of lung and
breast cancer cells in vitro, and reduced cancer cell pro-
tumorigenic and proinflammatory signaling. EC perlecan
silencing significantly changed this regulatory relationship,
eliminating the ability of ECs to inhibit cancer cell inva-
siveness via increased interleukin-6 secretion. Moreover,
implanting ECs embedded within porous matrices slowed
adjacent xenograft tumor growth and prevented architec-
tural degeneration, concomitantly reducing proliferative
and tumorigenic markers. Finally, lung carcinoma cells
pretreated with intact EC-conditioned media, but not media
conditioned with perlecan-silenced ECs, exhibited a
reduced micrometastatic burden after tail vein injection
[37]. These findings add to an emerging appreciation of
EC-regulatory effects that transcend their structural roles
and pave the way for improved characterization and control
of EC–cancer cross-talk interactions for the diagnosis,
prognosis, and treatment of cancer.
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